MX2016006270A - Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos. - Google Patents

Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Info

Publication number
MX2016006270A
MX2016006270A MX2016006270A MX2016006270A MX2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A
Authority
MX
Mexico
Prior art keywords
compositions
cells
human placental
placental perfusate
subpopulations
Prior art date
Application number
MX2016006270A
Other languages
English (en)
Spanish (es)
Inventor
P Gurney Jodi
Zhang Xiaokui
Herb Stacy
J Hariri Robert
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of MX2016006270A publication Critical patent/MX2016006270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2016006270A 2013-11-15 2014-11-14 Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos. MX2016006270A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361905076P 2013-11-15 2013-11-15
US201361905077P 2013-11-15 2013-11-15
PCT/US2014/065665 WO2015073800A2 (en) 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Publications (1)

Publication Number Publication Date
MX2016006270A true MX2016006270A (es) 2016-09-07

Family

ID=53058264

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006270A MX2016006270A (es) 2013-11-15 2014-11-14 Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.
MX2021003799A MX2021003799A (es) 2013-11-15 2016-05-13 Composiciones que comprenden celulas perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003799A MX2021003799A (es) 2013-11-15 2016-05-13 Composiciones que comprenden celulas perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Country Status (11)

Country Link
US (2) US20160279171A1 (enExample)
EP (1) EP3068432A4 (enExample)
JP (4) JP2016537362A (enExample)
KR (3) KR20210121277A (enExample)
CN (2) CN105916521A (enExample)
AU (3) AU2014348454A1 (enExample)
CA (1) CA2930573C (enExample)
MX (2) MX2016006270A (enExample)
RU (1) RU2016123361A (enExample)
WO (1) WO2015073800A2 (enExample)
ZA (1) ZA201603270B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707491B2 (en) * 2016-11-11 2023-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of treating neurodegenerative disorders
ES2977897T3 (es) * 2017-03-15 2024-09-02 Orca Biosystems Inc Composiciones y métodos para trasplantes de células madre hematopoyéticas
CN113395972A (zh) * 2018-11-30 2021-09-14 细胞结构公司 胎盘源性同种异体car-t细胞及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
AU2002243980B2 (en) * 2001-02-14 2007-08-23 Robert J. Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
WO2002064755A2 (en) * 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20080063652A1 (en) * 2004-03-29 2008-03-13 Cytomatrix, Llc Methods for Production of Regulatory T Cells and Uses Thereof
EP1957633B1 (en) * 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
WO2007079184A2 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
EP2471903B1 (en) * 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
NZ570614A (en) * 2006-01-23 2012-07-27 Athersys Inc Multipotent adult progenitor cell treatment of brain injuries and diseases
JP5260499B2 (ja) * 2006-05-11 2013-08-14 コード ブラッド サイエンス インコーポレイテッド 臍帯血幹細胞の回収方法及び使用方法
KR20090076989A (ko) * 2006-10-23 2009-07-13 안트로제네시스 코포레이션 태반 줄기세포군으로 뼈의 결함을 치료하기 위한 방법과 조성물
JP2010518812A (ja) * 2007-02-12 2010-06-03 アンスロジェネシス コーポレーション 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
US8273526B2 (en) * 2007-06-18 2012-09-25 Children's Hospital & Research Center At Oakland Method of isolating stem and progenitor cells from placenta
EP2205719A1 (en) * 2007-09-26 2010-07-14 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
US8263065B2 (en) * 2007-09-28 2012-09-11 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
AU2009316376B2 (en) * 2008-11-21 2015-08-20 Celularity Inc. Treatment of diseases, disorders or conditions of the lung using placental cells
WO2010105144A2 (en) * 2009-03-12 2010-09-16 University Of South Florida Method of disease-induced and receptor-mediated stem cell neuroprotection
WO2010141654A1 (en) * 2009-06-05 2010-12-09 Anthrogenesis Corporation Improved method of collecting placental cells
WO2011008277A2 (en) * 2009-07-14 2011-01-20 Massachusetts Institute Of Technology Hematopoietic stromal progenitor cells and uses thereof
US20110280849A1 (en) * 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
PT2556145T (pt) 2010-04-07 2016-10-25 Anthrogenesis Corp Angiogénese usando células estaminais placentárias
KR20230096132A (ko) * 2010-07-13 2023-06-29 셀룰래리티 인코포레이티드 천연 킬러 세포의 생성 방법
EP2651452A4 (en) 2010-12-17 2014-05-07 Anthrogenesis Corp TREATMENT OF BACKBONE INJURIES AND TRAUMATIC BRAIN DAMAGES WITH ADHESIVE CELLS DERIVED FROM AMNION
KR20210144909A (ko) * 2010-12-17 2021-11-30 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
US20120171180A1 (en) * 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising amnion derived adherent cells and platelet-rich plasma
US9925221B2 (en) * 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US20150225697A1 (en) * 2012-08-13 2015-08-13 Anthrogenesis Corporation Natural killer cells and uses thereof
US20160166618A1 (en) * 2012-10-19 2016-06-16 Anthrogenesis Corproation Treatment of pain using amnion derived adherent cells

Also Published As

Publication number Publication date
MX2021003799A (es) 2021-06-04
US20160279171A1 (en) 2016-09-29
KR20240023709A (ko) 2024-02-22
EP3068432A2 (en) 2016-09-21
US20190117705A1 (en) 2019-04-25
JP2024016037A (ja) 2024-02-06
AU2020202182A1 (en) 2020-04-16
AU2022215291A1 (en) 2022-09-01
AU2014348454A1 (en) 2016-06-02
WO2015073800A8 (en) 2015-12-17
JP2020019777A (ja) 2020-02-06
JP2022020622A (ja) 2022-02-01
RU2016123361A (ru) 2017-12-20
KR20210121277A (ko) 2021-10-07
CN113679740A (zh) 2021-11-23
JP2016537362A (ja) 2016-12-01
CA2930573A1 (en) 2015-05-21
KR20160098244A (ko) 2016-08-18
CA2930573C (en) 2023-12-05
ZA201603270B (en) 2022-09-28
WO2015073800A2 (en) 2015-05-21
AU2022215291A9 (en) 2022-11-24
EP3068432A4 (en) 2017-04-19
CN105916521A (zh) 2016-08-31
WO2015073800A3 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
MX2023001226A (es) Anticuerpos anti-lag-3.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MX2018015656A (es) Compuestos heterociclicos como antibacterianos.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
PH12015502767A1 (en) Sc-� cells and compositions and methods for generating the same
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201890201A1 (ru) Антибактериальные соединения
MX354955B (es) Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
BR112017006664A2 (pt) terapias de combinação
NZ709215A (en) Compositions comprising anti-cd38 antibodies and lenalidomide
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
MX381278B (es) Composición para la estimulación ovárica controlada.
PH12018500379A1 (en) Biopharmaceutical compositions
MX356163B (es) Anilinas sustituidas como antagonistas de ccr(4).
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12017501028A1 (en) Treatment of retinal degeneration using progenitor cells
NZ741785A (en) 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv
WO2016048861A3 (en) Heterocyclic compounds and use thereof
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.